tiprankstipranks

Quest Diagnostics price target raised to $182 from $172 at Truist

Truist analyst David MacDonald raised the firm’s price target on Quest Diagnostics (DGX) to $182 from $172 and keeps a Hold rating on the shares. The company’s organic revenue was up 5%, utilization remains solid, and Truist expects ongoing testing volume and robust 2024 M&A activity to provide an attractive tailwind, the analyst tells investors in a research note.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue